Trial Condition(s):

Prostate Cancer

Treatment Patterns in Castrate Resistant Prostate Cancer Patients with Bone Metastases in a Medicare Population

Bayer Identifier:

18273

ClinicalTrials.gov Identifier:

NCT02518698

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.

Inclusion Criteria
-  First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period
 -  Members age ≥ 55 to 89 years at index
 -  Medicare members with medical and pharmacy coverage; and
 -  Continuously enrolled during the pre- and post-index periods.
Exclusion Criteria
-  Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other metastases (ICD-9 198.x)) before the index date; and
 -  Members age ≥ 89 years of age at index date

Trial Summary

Enrollment Goal
1163
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Louisville, United States

Status
Completed
 

Trial Design